Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Cash from Investing Activities (2020 - 2025)

Beauty Health (SKIN) has disclosed Cash from Investing Activities for 6 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 48.18% to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.6 million, a 42.68% increase, with the full-year FY2024 number at -$6.8 million, up 78.44% from a year prior.
  • Cash from Investing Activities was -$1.1 million for Q3 2025 at Beauty Health, up from -$1.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$862000.0 in Q4 2024 to a low of -$21.7 million in Q1 2023.
  • A 5-year average of -$5.2 million and a median of -$2.8 million in 2022 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 98.15% in 2021; the steepest drop was 1478.77% in 2021.
  • Beauty Health's Cash from Investing Activities stood at -$8.5 million in 2021, then surged by 66.89% to -$2.8 million in 2022, then grew by 23.23% to -$2.2 million in 2023, then soared by 60.24% to -$862000.0 in 2024, then fell by 25.75% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Cash from Investing Activities are -$1.1 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.1 million (Q1 2025).